Zydus Cadila receives nod for type 2 Diabetes treatment drug

Zydus Cadila has received an approval from Drug Controller General of India (DGIA) for the use of Saroglitazar Magnesium in the treatment of type 2 Diabetes Mellitus as an additional therapy with Metformin.

Previously, the drug was approved in the year 2013, for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in India due to which, more than one million patients are being treated with Lipaglyn. Saroglitazar (Lipaglyn) is a novel drug. The recommended dose of Lipaglyn is four mg once a day, to be taken with the advice of a registered medical practitioner. The diabetes phase 3 clinical trial, which was a multi-centric, prospective, randomised, double-blind study was undertaken to evaluate the safety and efficacy of Saroglitazar 2 mg and 4 mg, as compared to Pioglitazone 30 mg in patients being positive for type 2 diabetes. According to Pankaj Patel, the Chairman of Zydus Group, insulin resistance continues to be one of the primary causes of diabetes and the huge unmet medical need for a safe and effective insulin sensitizer. Thus, Saroglitazar can be considered as an important scientific and medical breakthrough in order to develop medicines for patients suffering from type 2 diabetes mellitus. The need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance with the rise in diabetes cases in India.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics and vaccines.

On Monday, the stock of the company was trading at Rs 259.35, down by 0.42 per cent or Rs 1.10 per share. The 52-week high is Rs 352.30 and 52-week low is Rs 206.45 on BSE.